Clinical trial
Vaccine and Antibody Treatment of Prostate Cancer
NCT00113984 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00113984 |
|---|---|
| Title | Vaccine and Antibody Treatment of Prostate Cancer |
| Official title | Phase I Trial of a PSA Based Vaccine and an Anti-CTLA-4 Antibody in Adults With Metastatic Androgen Independent Prostrate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Biological, Drug |
| Interventions | PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM, MDX-010, Sargramostim |
| Enrollment | 30 |
| Start date | Jun 8, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Dec 1, 2011 |
| First posted | Jun 13, 2005 |
| Last update posted | Dec 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: